关注
Ron Keizer
Ron Keizer
Chief Scientific Officer, InsightRX
在 insight-rx.com 的电子邮件经过验证 - 首页
标题
引用次数
引用次数
年份
Clinical pharmacokinetics of therapeutic monoclonal antibodies
RJ Keizer, ADR Huitema, JHM Schellens, JH Beijnen
Clinical pharmacokinetics 49, 493-507, 2010
7642010
Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose
RJ Keizer, MO Karlsson, A Hooker
CPT: pharmacometrics & systems pharmacology 2 (6), 1-9, 2013
6732013
Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM
RJ Keizer, M Van Benten, JH Beijnen, JHM Schellens, ADR Huitema
Computer methods and programs in biomedicine 101 (1), 72-79, 2011
3602011
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
IH Bartelink, A Lalmohamed, EML van Reij, CC Dvorak, RM Savic, ...
The Lancet Haematology 3 (11), e526-e536, 2016
2422016
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients
TPC Dorlo, PPAM van Thiel, ADR Huitema, RJ Keizer, HJC de Vries, ...
Antimicrobial agents and chemotherapy 52 (8), 2855-2860, 2008
1992008
Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses
RJ Keizer, RS Jansen, H Rosing, B Thijssen, JH Beijnen, JHM Schellens, ...
Pharmacology research & perspectives 3 (2), e00131, 2015
1692015
Model‐informed precision dosing at the bedside: scientific challenges and opportunities
RJ Keizer, R Ter Heine, A Frymoyer, LJ Lesko, R Mangat, S Goswami
CPT: pharmacometrics & systems pharmacology 7 (12), 785-787, 2018
1122018
Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice
DJ Buurman, JM Maurer, RJ Keizer, JGW Kosterink, G Dijkstra
Alimentary pharmacology & therapeutics 42 (5), 529-539, 2015
792015
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080
RJ Keizer, A Gupta, MR Mac Gillavry, M Jansen, J Wanders, JH Beijnen, ...
Journal of pharmacokinetics and pharmacodynamics 37, 347-363, 2010
652010
The effect of famotidine, a MATE1-selective inhibitor, on the pharmacokinetics and pharmacodynamics of metformin
JE Hibma, AA Zur, RA Castro, MB Wittwer, RJ Keizer, SW Yee, ...
Clinical pharmacokinetics 55, 711-721, 2016
602016
Model-informed precision dosing of vancomycin in hospitalized children: implementation and adoption at an academic children’s hospital
A Frymoyer, HT Schwenk, Y Zorn, L Bio, JD Moss, B Chasmawala, ...
Frontiers in Pharmacology 11, 551, 2020
472020
Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses
RJ Keizer, AS Zandvliet, JH Beijnen, JHM Schellens, ADR Huitema
The AAPS journal 14, 601-611, 2012
462012
Individualized empiric vancomycin dosing in neonates using a model-based approach
A Frymoyer, C Stockmann, AL Hersh, S Goswami, RJ Keizer
Journal of the Pediatric Infectious Diseases Society 8 (2), 97-104, 2019
452019
Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development
MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ...
CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015
432015
New paradigm for translational modeling to predict long‐term tuberculosis treatment response
IH Bartelink, N Zhang, RJ Keizer, N Strydom, PJ Converse, KE Dooley, ...
Clinical and translational science 10 (5), 366-379, 2017
402017
Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients
R Ter Heine, RJ Keizer, K van Steeg, EJ Smolders, M van Luin, HJ Derijks, ...
British journal of clinical pharmacology 86 (12), 2497-2506, 2020
392020
A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors
JH Hughes, RJ Keizer
CPT: pharmacometrics & systems pharmacology 10 (10), 1150-1160, 2021
382021
Continuous learning in model‐informed precision dosing: a case study in pediatric dosing of vancomycin
JH Hughes, DMH Tong, SS Lucas, JD Faldasz, S Goswami, RJ Keizer
Clinical Pharmacology & Therapeutics 109 (1), 233-242, 2021
372021
Oxymorphone active uptake at the blood–brain barrier and population modeling of its pharmacokinetic–pharmacodynamic relationship
MW Sadiq, E Boström, R Keizer, S Bjorkman, M Hammarlund-Udenaes
Journal of pharmaceutical sciences 102 (9), 3320-3331, 2013
372013
Personalized tuberculosis treatment through model-informed dosing of rifampicin
SW van Beek, R Ter Heine, RJ Keizer, C Magis-Escurra, RE Aarnoutse, ...
Clinical pharmacokinetics 58, 815-826, 2019
332019
系统目前无法执行此操作,请稍后再试。
文章 1–20